Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00200200
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-29
First Post:
2005-09-12
Brief Title:
Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy WithWithout Bevacizumab for Hepatic Metastases From Colorectal Cancer
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
Randomized Ph II Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With IV Systemic Chemo WithWithout Bevacizumab mAB to Vascular Endothelial Growth Factor-A in Patients With Resected Hepatic Metastases From Colorectal Cancer
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether the addition of bevacizumab to hepatic arterial therapy with floxuridine FUDR and dexamethasone Dex regional chemotherapy and either oxaliplatin or CPT-11 plus 5-fluorouracil and leucovorin systemic chemotherapy will increase disease free survival in patients who have undergone liver resection The patient will be randomized a computer generated decision as in the flip of a coin to receive or not to receive bevacizumab in addition to regional and systemic chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None